Sono-Tek Corporation (SONO) 10-K Summary
Business Context and Reporting Period
Company: Sono-Tek Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: February 28, 2010
Business Overview: Sono-Tek develops, manufactures, and sells ultrasonic liquid atomizing nozzles and coating systems. The company operates in a single segment: spraying and coating systems. Key markets include electronics (circuit board fluxing), medical devices (stent coating), advanced energy (fuel cells/solar), and industrial wide-area coating (glass, textiles, food). The company is a smaller reporting company with no securities registered under Section 12(b).
Key Financial Metrics
| Metric | Fiscal 2010 | Fiscal 2009 |
|---|---|---|
| Net Sales | $7,242,324 | $6,408,796 |
| Gross Profit | $3,674,150 | $2,850,440 |
| Gross Margin | 51% | 44% |
| Net Income (Loss) | $81,676 | ($1,513,028) |
| Operating Cash Flow | $493,980 | ($792,298) |
| Working Capital | $3,075,362 | $2,897,852 |
| Current Ratio | 3.0 to 1 | 3.5 to 1 |
| Total Debt (Current + Long Term) | $369,349 | $292,853 |
| Cash and Equivalents | $1,787,516 | $1,472,054 |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased by approximately 13% ($833,000) driven by higher sales of programmable XYZ precision coating units, stent coater units, SonoFlux EZ units, and Hypersonic units. This offset declines in fluxer units, WideTrack units, and spray dryer systems.
- Profitability Turnaround: The company returned to profitability with a net income of $82,000, compared to a net loss of $1.51 million in 2009. The 2009 loss was significantly impacted by a $612,000 non-cash valuation reserve increase on deferred tax assets.
- Margin Expansion: Gross margin improved from 44% to 51%, attributed to the higher mix of high-margin stent coater and precision coating unit sales.
- Expense Reduction: Operating expenses decreased by approximately $177,000. Research and development costs fell by $86,000, and marketing/selling costs dropped by $39,000 due to reduced travel and trade show expenses.
- Geographic Shift: Foreign sales increased to 65% of total revenue ($4.74 million) from 59% ($3.79 million) in the prior year, with a 23% increase in sales to Asian customers.
Guidance, Outlook, and Risks
Management Commentary: Management highlights successful diversification into medical device, advanced energy, and wide-area coating markets, reducing reliance on the cyclical electronics industry. The company emphasizes its international growth, which now accounts for the majority of revenue.
Liquidity and Capital Resources: The company maintains a strong liquidity position with a current ratio of 3.0. It holds a $500,000 revolving line of credit (with $350,000 outstanding) and a $150,000 equipment facility (with $19,000 outstanding). The line of credit is collateralized by all company assets and requires a 30-day annual payoff.
Risks and Contingencies:
- Customer Concentration: One customer accounted for 6.8% of sales in 2010. One customer accounted for 10.1% of accounts receivable.
- Market Dependence: While diversified, the electronics industry remains a principal market, and downturns in printed circuit board production can impact sales.
- Intellectual Property: The business relies on patents and unpatented know-how; enforcement of these rights is critical.
- Forward-Looking Statements: Future performance depends on general economic conditions, timely development of new products, and the ability to achieve increased sales volume.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of the 23% sales growth in Asian markets and the specific contribution of new product lines (stent coaters, precision units) to the improved gross margin.
- Debt Covenants: Confirm the terms of the $500,000 revolving credit line, specifically the requirement for a 30-day annual payoff and the impact of the full asset collateralization.
- Customer Concentration: Assess the risk associated with the single customer representing 6.8% of sales and 10.1% of receivables.
- Tax Position: Review the status of the $2.176 million net operating loss carryforwards and the valuation allowance, noting the significant non-cash tax expense in the prior year.
- Stock Option Dilution: Note that 1,229,768 options are outstanding with a weighted average exercise price of $1.11, which could impact future earnings per share if exercised.